Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assists in connection with the acquisition of Alergovet S.L.
Mandate

Vinge assists in connection with the acquisition of Alergovet S.L.

December 14, 2016

Vinge assists Nextmune Holding B.V., primarily owned by Fidelio Capital and Premune, in connection with the acquisition of the shares in Alergovet S.L. Alergovet is a leading company in Southern Europe focused on the diagnoses and treatment of atopic dermatitis for companion animals and horses, and offers high quality allergy tests and allergen-specific immunotherapy treatment for companion animals and horses.

Vinge’s team consists of partner Jonas Johansson together with, among others, associates Albert Wållgren, Linn Adelwald, Isabell Nielsen, Andréa Nicolin, Gustav Tengblad and Sofia Bergenstråhle.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026